Abstract:Preeclampsia was formerly defined as a multisystemic disorder characterized by new onset of hypertension (i.e. systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg) and proteinuria (> 300 mg/24 h) arising after 20 weeks of gestation in a previously normotensive woman. Recently, the American College of Obstetricians and Gynecologists has stated that proteinuria is no longer required for the diagnosis of preeclampsia. This complication of pregnancy remains a leading cause of maternal morbidity and mortality. Clinical signs appear in the second half of pregnancy, but initial pathogenic mechanisms arise much earlier. The cytotrophoblast fails to remodel spiral arteries, leading to hypoperfusion and ischemia of the placenta. The fetal consequence is growth restriction. On the maternal side, the ischemic placenta releases factors that provoke a generalized maternal endothelial dysfunction. The endothelial dysfunction is in turn responsible for the symptoms and complications of preeclampsia. These include hypertension, proteinuria, renal impairment, thrombocytopenia, epigastric pain, liver dysfunction, hemolysis-elevated liver enzymes-low platelet count (HELLP) syndrome, visual disturbances, headache, and seizures. Despite a better understanding of preeclampsia pathophysiology and maternal hemodynamic alterations during preeclampsia, the only curative treatment remains placenta and fetus delivery. At the time of diagnosis, the initial objective is the assessment of disease severity. Severe hypertension (SBP ≥ 160 mm Hg and/or DBP ≥ 110 mmHg), thrombocytopenia < 100.000/μL, liver transaminases above twice the normal values, HELLP syndrome, renal failure, persistent epigastric or right upper quadrant pain, visual or neurologic symptoms, and acute pulmonary edema are all severity criteria. Medical treatment depends on the severity of preeclampsia, and relies on antihypertensive medications and magnesium sulfate. Medical treatment does not alter the course of the disease, but aims at preventing the occurrence of intracranial hemorrhages and seizures. The decision of terminating pregnancy and perform delivery is based on gestational age, maternal and fetal conditions, and severity of preeclampsia. Delivery is proposed for patients with preeclampsia without severe features after 37 weeks of gestation and in case of severe preeclampsia after 34 weeks of gestation. Between 24 and 34 weeks of gestation, conservative management of severe preeclampsia may be considered in selected patients. Antenatal corticosteroids should be administered to less than 34 gestation week preeclamptic women to promote fetal lung maturity. Termination of pregnancy should be discussed if severe preeclampsia occurs before 24 weeks of gestation. Maternal end organ dysfunction and non-reassuring tests of fetal well-being are indications for delivery at any gestational age. Neuraxial analgesia and anesthesia are, in the absence of thrombocytopenia, strongly considered as first line anesthetic techniques in preeclamptic patients. Airway edema and tracheal intubation-induced elevation in blood pressure are important issues of general anesthesia in those patients. The major adverse outcomes associated with preeclampsia are related to maternal central nervous system hemorrhage, hepatic rupture, and renal failure. Preeclampsia is also a risk factor for developing cardiovascular disease later in life, and therefore mandates long-term follow-up.

Chronic Hypertension Superimposed on Preeclampsia at 13 Gestational Weeks: a Case Report with Review.

The Feto-Maternal Outcomes and Incidence of Early-and Late-Onset Preeclampsia

Chronic hypertension diagnosed before or during pregnancy and its effects on pregnancy outcomes

Maternal and Perinatal Prognosis of Pregnancy with Chronic Hypertension and Analysis of Associated Factors

Comparing Maternal and Perinatal Outcomes in Pregnancies Complicated by Preeclampsia Superimposed Chronic Hypertension and Preeclampsia Alone

Analysis of risk factors of preeclampsia in pregnant women with chronic hypertension and its impact on pregnancy outcomes

Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study

The Risk of Persistent Hypertension and Chronic Kidney Disease in Early- and Late-Onset Preeclampsia: A Report From Developing Country

Clinical characteristics of pregnant women complicated with early onset preeclampsia with prior cesarean section due to hypertensive disorders of pregnancy

Hypertension arising after 20 weeks of gestation: gestational hypertension or masked chronic hypertension?

[Clinical features and prognosis of early-onset preeclampsia].

RISK FACTORS FOR CHRONIC HYPERTENSION 5 YEARS AFTER A PREGNANCY COMPLICATED BY PREECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

The clinical features and prognostic analysis of early-onset preeclampsia

Chronic Hypertension in Pregnancy and Placenta-Mediated Complications Regardless of Preeclampsia

A Comprehensive Review of Hypertension in Pregnancy

Analysis of postpartum hypertension in women with preeclampsia

Preeclampsia: an update

EP12.08: Risk of superimposed pre‐eclampsia and adverse outcomes in pregnant women with chronic hypertension

30 Case Analysis of Severe Pregnancy Induced Hypertension Syndrome

Update in pre-eclampsia

Pregnancy Induced Hypertension and its Management